Haskell C M, Mendoza E, Pisters K M, Fossella F V, Figlin R A
Cancer Center and Department of Medicine, West Los Angeles VA Medical Center (111-N), CA 90073, USA.
Invest New Drugs. 1998;16(1):81-5. doi: 10.1023/a:1006018610986.
Fifteen patients with Stage IIIB or IV non-small cell lung cancer gave informed consent to receive three or more 96-hour infusions of ATP at a dose of 50 mcg/kg/min or higher to determine whether ATP has antineoplastic activity against this tumor type and to better define the spectrum of toxicity for ATP given as a single agent. There were no objective complete or partial responses observed. The median survival of the overall group was 187 days and the median time to tumor progression was 113 days. The major toxic side effects were chest pain and dyspnea, leading to the cessation of treatment in 5 patients. We conclude that ATP at this dose and schedule of administration is an inactive agent in patients with advanced non-small cell lung cancer.
15例ⅢB期或Ⅳ期非小细胞肺癌患者签署知情同意书，接受三次或更多次96小时的ATP输注，剂量为50微克/千克/分钟或更高，以确定ATP对该肿瘤类型是否具有抗肿瘤活性，并更好地界定ATP作为单一药物的毒性谱。未观察到客观的完全或部分缓解。整个组的中位生存期为187天，肿瘤进展的中位时间为113天。主要的毒性副作用是胸痛和呼吸困难，导致5例患者停止治疗。我们得出结论，在此剂量和给药方案下，ATP对晚期非小细胞肺癌患者是一种无效药物。
